ASCO: With Opdivo-Yervoy combo, Bristol Myers calls Roche and AstraZeneca's bets in first-line liver cancer

Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too.

The BMS immunotherapy duo pared down the risk of death by 21% compared with either Merck and Eisai’s Lenvima or Bayer’s Nexavar in patients with previously untreated advanced hepatocellular carcinoma, according to data from the phase 3 CheckMate-9DW trial.